Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Athena Diagnostics | RCV000517728 | SCV000613972 | uncertain significance | not specified | 2017-02-24 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV000701102 | SCV000829885 | uncertain significance | LAMA2-related muscular dystrophy | 2021-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine with glycine at codon 1762 of the LAMA2 protein (p.Arg1762Gly). The arginine residue is weakly conserved and there is a moderate physicochemical difference between arginine and glycine. This variant is present in population databases (rs746492572, ExAC 0.002%). This variant has not been reported in the literature in individuals affected with LAMA2-related conditions. ClinVar contains an entry for this variant (Variation ID: 447688). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV004984936 | SCV005607116 | uncertain significance | Inborn genetic diseases | 2024-06-26 | criteria provided, single submitter | clinical testing | The c.5284C>G (p.R1762G) alteration is located in exon 37 (coding exon 37) of the LAMA2 gene. This alteration results from a C to G substitution at nucleotide position 5284, causing the arginine (R) at amino acid position 1762 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |